Form 4: Edwards Lifesciences Executive Donald E. Bobo Jr. Reports Stock and Option Grants

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Summary

• On May 7, 2024, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences Corp, reported transactions involving the company's stock.
• Bobo acquired 6,700 shares of common stock and disposed of 619 shares to satisfy tax obligations at a price of $85.09.
• Following these transactions, Bobo directly owns 47,749.7184 shares of common stock.
• Bobo also indirectly owns 38,615.0363 shares through a 401(k) and 135,152 shares through a trust.
• Additionally, Bobo was granted options to acquire 39,600 shares of common stock at an exercise price of $85.84, which become exercisable in monthly installments starting June 7, 2024, and expire on May 6, 2031.
• He also received 6,700 performance-based restricted stock units that vest on May 7, 2027, contingent on achieving certain performance goals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting required information about executive stock transactions. The grants are a positive sign of confidence in the executive and the company's future, but the tax-related disposal is slightly negative.

Positives

• The grant of stock options and restricted stock units to a key executive aligns their interests with the long-term performance of the company.
• The vesting schedule of the options and restricted stock units encourages continued service and achievement of performance goals.

Negatives

• The disposal of 619 shares, while for tax obligations, represents a slight decrease in Bobo's direct holdings.

Risks

• The vesting of the performance-based restricted stock units is contingent on achieving certain performance goals, which may not be met.
• The value of the stock options is dependent on the future stock price of Edwards Lifesciences.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest an expectation of continued growth and performance from Edwards Lifesciences.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the medical device industry. It reflects standard practices for incentivizing and retaining key personnel.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of executive compensation in the medical device industry, used by companies like Medtronic, Abbott, and Boston Scientific.
• The vesting schedules and performance-based conditions are also typical, designed to align executive incentives with shareholder value creation.
• The size of the grant is likely benchmarked against peer companies based on the executive's role and responsibilities.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign, aligning executive interests with company performance.
• Employees may see the grants as a reflection of the company's commitment to rewarding key personnel.

Key Dates